ABIOMED (NASDAQ:ABMD) Getting Somewhat Positive Media Coverage, Study Shows

Media coverage about ABIOMED (NASDAQ:ABMD) has been trending somewhat positive on Saturday, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. ABIOMED earned a media sentiment score of 0.19 on Accern’s scale. Accern also assigned media coverage about the medical equipment provider an impact score of 46.4271362620848 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

These are some of the news headlines that may have impacted Accern Sentiment Analysis’s scoring:

Shares of ABIOMED (NASDAQ:ABMD) traded up $4.96 during midday trading on Friday, hitting $215.11. 283,326 shares of the stock traded hands, compared to its average volume of 202,602. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.84 and a quick ratio of 5.20. ABIOMED has a 52-week low of $103.53 and a 52-week high of $216.15. The stock has a market cap of $9,292.02, a PE ratio of 105.97, a price-to-earnings-growth ratio of 2.77 and a beta of 0.15.

ABIOMED (NASDAQ:ABMD) last posted its quarterly earnings data on Thursday, October 26th. The medical equipment provider reported $0.54 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.38 by $0.16. ABIOMED had a net margin of 18.27% and a return on equity of 13.89%. The company had revenue of $132.80 million for the quarter, compared to analyst estimates of $131.18 million. During the same period in the prior year, the company posted $0.20 EPS. The firm’s revenue for the quarter was up 28.9% on a year-over-year basis. equities analysts forecast that ABIOMED will post 2.41 EPS for the current fiscal year.

Several research analysts recently weighed in on the stock. SunTrust Banks assumed coverage on shares of ABIOMED in a report on Friday, September 29th. They issued a “buy” rating and a $195.00 target price for the company. Jefferies Group upped their target price on shares of ABIOMED from $175.00 to $208.00 and gave the stock a “buy” rating in a report on Friday, September 29th. Zacks Investment Research raised shares of ABIOMED from a “hold” rating to a “buy” rating and set a $220.00 price objective for the company in a report on Tuesday, November 7th. Piper Jaffray Companies reissued a “buy” rating on shares of ABIOMED in a report on Thursday, January 4th. Finally, BidaskClub raised shares of ABIOMED from a “hold” rating to a “buy” rating in a report on Thursday. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $199.67.

In other news, Director Dorothy E. Puhy sold 6,364 shares of the stock in a transaction that occurred on Monday, October 30th. The shares were sold at an average price of $179.08, for a total transaction of $1,139,665.12. Following the transaction, the director now directly owns 39,532 shares in the company, valued at $7,079,390.56. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, VP Michael G. Howley sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, October 30th. The shares were sold at an average price of $178.64, for a total transaction of $1,786,400.00. Following the completion of the sale, the vice president now owns 56,757 shares of the company’s stock, valued at $10,139,070.48. The disclosure for this sale can be found here. Corporate insiders own 7.00% of the company’s stock.

TRADEMARK VIOLATION WARNING: This article was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/01/13/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-abiomed-abmd-share-price.html.

ABIOMED Company Profile

ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.

Insider Buying and Selling by Quarter for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply